Why Do I Need a Bone Marrow Biopsy for Myeloma?
What happens during the 20-minute procedure, how to read your plasma cell and FISH results, and why testing again at relapse matters
Medical Disclaimer: This guide is synthesized from international clinical consensus guidelines and peer-reviewed literature. It is for educational purposes only and does not substitute for professional medical advice. Always consult your oncology team regarding diagnostic and treatment decisions.
💡 The Short Answer
A bone marrow aspirate and core biopsy is a safe, 20-minute outpatient procedure taken from the back of your hip bone—nowhere near your spine—that serves as the essential gold standard for diagnosing multiple myeloma. While blood and urine tests only measure the proteins myeloma cells release, a bone marrow exam looks directly inside the marrow to count your clonal plasma cell percentage across the 10% and 60% thresholds (always using the higher number between the liquid aspirate and the CD138-stained core biopsy), checks specimen quality using the first 2 to 3 mL draw and CD138 cell sorting, and reads your tumor genetics under the 2025 IMS/IMWG rules. Just as importantly, repeating the bone marrow biopsy and FISH test if myeloma relapses allows your doctor to spot newly acquired high-risk changes like del(17p) or 1q21 amplification and upgrade your treatment immediately.
Why This Matters
Hearing that you need a "bone marrow biopsy" is often the most nerve-wracking moment of a multiple myeloma workup. Almost every patient walks into the clinic asking the same questions: Will it hurt? Does the needle go into my spine? Can we just do a blood test instead?
Before you worry, take a deep breath and keep three reassuring facts in mind:
- It goes into your hip bone, nowhere near your spinal cord: A bone marrow biopsy is not a spinal tap. The doctor takes the sample from the back of your pelvic bone (right where your back pockets sit), so it cannot touch your spinal cord or cause paralysis.
- Blood tests only show the "smoke," while the bone marrow shows the "fire": Blood tests detect the M-protein released into your circulation, but only a bone marrow biopsy can count the actual myeloma cells, read their genetic blueprint, and save their DNA fingerprint for future deep-remission (
MRD) tracking. - Knowing what makes a "good sample" protects you from repeat procedures: Understanding two simple quality rules—using the first syringe pull for genetics and sorting out
CD138plasma cells—ensures your very first biopsy gives clear, reliable answers.
If you are reviewing your initial lab work, see our companion guide on interpreting blood, urine, and imaging reports. This guide walks you through why the test is needed, what the 20-minute procedure actually feels like, how to read your results without a medical degree, and why checking the bone marrow again at relapse is so valuable.
📖 Key Terms in Plain English
| Term | Plain-English Meaning |
|---|---|
| Posterior Iliac Crest (Back of the Hip Bone) | The wide, flat edge at the back of your pelvic bone just below your waist—the safe, standard spot where bone marrow samples are taken |
| Bone Marrow Aspirate (Liquid Sample) | A small syringe of liquid bone marrow (looks like thick blood) used to examine individual cells, run FISH genetics, and check Minimal Residual Disease (MRD) |
| Trephine Core Biopsy (Solid Sample) | A tiny, solid cylinder of spongy bone tissue (about the size of a pencil lead, 1.5 to 2.0 cm long) that shows how tightly myeloma cells are packed together |
| Hemodilution (Blood Dilution) | When normal blood mixes into the liquid bone marrow syringe during the draw, making the liquid plasma cell percentage look artificially low |
| CD138 Cell Sorting (Enrichment) | A crucial lab step that uses tiny magnetic beads to pull out pure CD138-positive myeloma cells before running genetic FISH tests so nothing is missed |
| Clonal Evolution (Tumor "Upgrading") | When surviving myeloma cells pick up new genetic changes over time—such as a new del(17p) or 1q21 amplification—making a repeat biopsy at relapse essential |
1. Why Blood Tests Aren't Enough: What Only a Bone Marrow Biopsy Can Tell You
Think of your bone marrow as the "factory" where blood cells are made, and the M-protein in your blood as the "packages" shipped out of that factory. Blood and urine tests are great at counting the packages on the highway, but your doctor must look inside the factory itself to answer four critical questions:
- How crowded is the factory? (Confirming the diagnosis): By international rules, diagnosing multiple myeloma requires proving that clonal plasma cells make up at least
10%of your bone marrow (or≥ 60%, which automatically defines active myeloma requiring immediate treatment even if you have zero symptoms). - Are there "quiet" myeloma cells that don't show up in blood?: In a small percentage of patients—and sometimes after several lines of treatment—myeloma cells stop releasing M-protein or light chains into the blood altogether. Only a bone marrow exam and whole-body imaging can see them.
- What is the tumor's genetic personality? (Risk profiling): Blood tests cannot read the chromosomes inside your bone marrow plasma cells. The liquid marrow sample lets the lab run
FISHand DNA sequencing to see whether your myeloma is standard-risk or high-risk. - What does your tumor's "DNA barcode" look like? (Archiving for future MRD): At your very first biopsy, the lab records the unique genetic barcode of your myeloma cells. Later, when treatment drives your blood markers down to zero, your doctor uses that saved barcode to run Minimal Residual Disease (MRD) testing—checking if even 1 myeloma cell is hiding among 100,000 (
10⁻⁵) or 1,000,000 (10⁻⁶) healthy cells.
Data Sources: NCCN Guidelines v2.2027 (MYEL-1, MYEL-E); IMF Patient Handbook (2025).
2. Step-by-Step: What Actually Happens During the 20-Minute Procedure
A bone marrow aspirate and biopsy is done right in an outpatient procedure room. While the entire appointment takes about 30 minutes, the actual sampling part lasts only 5 to 10 minutes. Both the liquid aspirate and the solid core biopsy are taken from the exact same numbed spot on the back of your hip bone:
| Procedure Step & Time | What the Clinician Does | What You Actually Feel & How to Make It Easier |
|---|---|---|
| Step 1: Positioning & Numbing (5–10 mins) | You lie comfortably on your stomach or side; the clinician cleans the skin over the back of your hip and injects local lidocaine to numb the skin and the surface of the bone | A quick pinch and a brief warm stinging for 10 seconds as the numbing medicine goes in, followed by numbness (ask in advance for light IV twilight sedation if you feel anxious) |
| Step 2: Drawing the Liquid Marrow—Aspirate (1–2 mins) | A thin hollow needle is guided into the numbed hip bone, and the clinician pulls back on a small syringe to draw liquid marrow | A brief, deep suction or cramping ache down the back of your hip or leg that lasts only 3 to 5 seconds per syringe pull; blowing air out slowly like blowing out birthday candles helps relax your muscles |
| Step 3: Taking the Solid Core—Biopsy (2–3 mins) | Through the same numbed spot, the clinician gently advances and rocks a core needle to collect a pencil-lead-sized cylinder (1.5 to 2.0 cm) of spongy marrow | Firm pushing pressure and a dull rocking or vibration feeling in your hip—because the bone surface is numb, you should feel pressure rather than sharp pain |
| Step 4: Pressure Bandage & Rest (5–10 mins) | The needle is removed (no stitches are needed); a tight pressure bandage is taped over the spot and you lie on your back for 10–15 minutes so your body weight presses on the bandage | Mild dull soreness, similar to bumping your hip against the corner of a table; you walk out and go home the same day |
What This Means for You: You do not have to "tough it out" in silence. Before the procedure starts, ask your doctor to wait a full 2 to 3 minutes after injecting the lidocaine so the surface of the bone is completely numb, and do not hesitate to request oral anti-anxiety medication or light IV sedation if your cancer center offers it.
Aftercare Rule: Never Take Ibuprofen or Naproxen for Post-Biopsy Soreness
Keep your bandage dry for 24 hours (no baths, swimming, or hot tubs). It is normal to have a dull ache in your hip for 2 to 3 days. If you need a pain reliever, ask your care team about plain acetaminophen (Tylenol)—never take over-the-counter NSAID painkillers like ibuprofen (Advil/Motrin), naproxen (Aleve), or aspirin without approval, because NSAIDs can harm multiple myeloma kidneys and increase bleeding at the biopsy site.
Data Sources: IMF Patient Handbook (2025); NCCN Guidelines for Patients: Multiple Myeloma.
3. Reading Your First Report: Sample Quality, Cell Counts, and FISH Genetics
Your bone marrow results usually come back in two waves: the cell count report arrives in 2 to 4 days, and the genetic FISH report arrives in 7 to 14 days. Here is how to read the four sections that matter most to you:
| Report Section | What to Look For on Your Report | Plain-English Meaning for Your Care |
|---|---|---|
| 1. Specimen Quality (Adequacy Check) | • Aspirate notes "Spicules (particles) present"; • Core biopsy length is ≥ 1.5 to 2.0 cm; • Genetics run on "CD138-enriched" cells from the first 2 to 3 mL draw | Proves the doctor got true bone marrow rather than diluted blood, and confirms the lab purified the myeloma cells before testing their DNA |
| 2. Clonal Plasma Cell % (Aspirate vs. Core Biopsy) | • < 10%: MGUS range; • 10%–59%: Smoldering MM (or Active MM if CRAB/SLiM present); • ≥ 60%: Active MM requiring treatment | Always look for the higher percentage between the liquid aspirate smear and the solid CD138-stained core biopsy; doctors always go by the higher number |
| 3. Clonality (Kappa vs. Lambda Restriction) | Flow cytometry or staining shows cells are exclusively kappa-restricted or lambda-restricted (matching your blood light chain type) | Confirms the plasma cells are identical clones from one single abnormal parent cell rather than a normal immune reaction to an infection |
| 4. FISH & NGS Genetics (2025 IMS/IMWG Rules) | Checks for del(17p) (≥ 20% cells) / TP53, t(4;14), t(14;16), t(14;20), 1q21+, del(1p32), and t(11;14) | Tells your doctor whether your disease is Standard-Risk (~80% of patients, including t(11;14) or an isolated 1q+) or High-Risk (~20%), shaping your treatment intensity |
What This Means for You: Two things on a first bone marrow report confuse almost every patient:
- Why the liquid count and solid count rarely match: Suppose your liquid aspirate says
6% plasma cellswhile your solid core biopsy says28% CD138+ plasma cells. Did the lab make a mistake? No. Myeloma cells grow in uneven clumps inside the bone (like raisins in a loaf of bread), and sucking liquid marrow into a syringe pulls in normal blood that waters down the liquid count. The solid28%core biopsy is your true number. - Why "CD138-enriched" is the magic phrase on your FISH report: If a lab runs
FISHgenetics on raw, unsorted bone marrow fluid, normal white blood cells outnumber the myeloma cells and can hide a chromosome change, giving a false "normal" result. Seeing"CD138-enriched"(or"plasma cell sorted") on your report means the lab used magnetic beads to isolate pure myeloma cells first, so you can trust the genetic result 100%.
Data Sources: NCCN Guidelines v2.2027 (MYEL-B); 2025 IMS/IMWG Consensus Genomic Staging; EHA-EMN 2025 Guidelines.
4. Why You Need a New Bone Marrow Biopsy If Myeloma Relapses
If your myeloma comes back months or years after initial treatment, your doctor will likely recommend a repeat bone marrow biopsy and FISH panel. Patients understandably ask: "Didn't we already check my genes when I was first diagnosed? Do genes really change?"
Your personal inherited DNA never changes, but the DNA inside myeloma tumor cells can change over time—a process doctors call clonal evolution.
What Stays the Same vs. What Can Change at Relapse
Think of your myeloma as a garden of weeds. Your first treatment wipes out 99% of the easy-to-kill weeds, but over time, a tiny stubborn seed that survived can sprout with new "armor" to resist medication:
- What stays the same from Day 1: Your original starting chromosome swaps—such as
t(11;14)ort(4;14)—are the tumor's permanent birthmark and never switch to a different translocation. - What can newly appear at relapse (del(17p) and 1q21 amplification): Even if your genetics were 100% standard-risk at diagnosis, relapsed myeloma cells can newly lose part of chromosome 17 (
del(17p)or a TP53 gene mutation, which is found in ~8%–10% of new patients but up to 30%–50%+ of patients after multiple relapses) or gain extra copies of chromosome 1 (1q21gain with 3 copies, or1q21amplification with≥ 4 copies, ordel(1p32)). - Checking if immunotherapy targets are still present: In later relapses after
CAR-Tor bispecific antibodies, a repeat bone marrow test can also check whether the myeloma cells still carry surface targets likeBCMAorGPRC5D, helping your doctor pick the next therapy that is guaranteed to lock onto the cells.
What This Means for You: Spending 20 minutes to repeat a bone marrow biopsy and CD138-sorted FISH test at relapse can be a game-changer. If the new biopsy reveals a newly acquired del(17p), TP53 mutation, or 1q21 amplification, your oncologist knows right away that your myeloma has shifted into a higher-risk gear—and can skip gentle older combinations in favor of powerful CAR-T cell therapy or bispecific antibodies, or next-generation clinical trials.
Data Sources: NCCN Guidelines v2.2027 (MYEL-4, MYEL-B); 2025 IMS/IMWG Consensus Recommendations; EHA-EMN 2025 Guidelines.
Common Pitfalls to Avoid
Pitfall 1: Delaying Diagnosis Because You Fear the Needle Hits the Spine
❌ The Pitfall: Putting off a recommended bone marrow biopsy for months out of fear that the needle goes into the spine and could cause nerve damage or paralysis.
✅ The Right Move: Reassure yourself and your family that the sample is taken from the back of the pelvic hip bone, far away from the spinal cord. Ask your clinic for generous local lidocaine numbing or light twilight sedation so the 20-minute visit is comfortable and stress-free.
Pitfall 2: Taking Ibuprofen or Naproxen for Hip Soreness After the Biopsy
❌ The Pitfall: Reaching for ibuprofen (Advil/Motrin), naproxen (Aleve), or aspirin at home when the numbing medicine wears off and your hip feels bruised.
✅ The Right Move: Avoid all NSAID pain relievers, which can strain the kidneys in multiple myeloma and increase bruising. Use plain acetaminophen (if approved by your doctor) and keep the pressure dressing dry for 24 hours.
Pitfall 3: Trusting a Low Liquid Aspirate Count Without Checking the Core Biopsy
❌ The Pitfall: Seeing "5% plasma cells" on the early liquid aspirate report and assuming you only have MGUS, while ignoring the solid core biopsy report that comes out two days later showing "25% CD138-positive plasma cells."
✅ The Right Move: Always wait for both reports—the liquid aspirate and the solid CD138-stained core biopsy—and remember that your true plasma cell count is whichever percentage is higher.
Pitfall 4: Skipping a Repeat Bone Marrow Biopsy When Myeloma Relapses
❌ The Pitfall: Declining a bone marrow biopsy at relapse because "we already know I was standard-risk three years ago."
✅ The Right Move: Say yes to a repeat bone marrow biopsy with CD138-sorted FISH and TP53 testing at relapse so your doctor can check for newly acquired del(17p) or 1q21 amplification and choose the strongest next-line treatment.
Summary: Your Quick Decision Guide
Bone Marrow Biopsy Architecture: Dual Samples, Quality Rules & Relapse Surveillance
How liquid aspirate and solid core biopsy work together to count plasma cells, profile tumor genetics, and catch clonal evolution
Safe 20-Minute Hip Procedure (Posterior Iliac Crest—Never the Spine)
The sample is taken from the back of your pelvic hip bone right where your back pockets sit—nowhere near your spinal cord. With thorough local lidocaine numbing (and optional mild twilight sedation), sampling is completed in 5 to 10 minutes.
CD138 Cell Sorting, FISH Genetics & Baseline Barcode
- CD138 Magnetic Enrichment: Separates pure myeloma cells before FISH testing so normal white blood cells cannot hide chromosome mutations.
- 2025 IMS/IMWG Risk Panel: Identifies del(17p) (≥20% cutoff), 1q21+ (≥4 copies high-risk), t(4;14), and t(11;14).
- Baseline Tumor DNA Fingerprint: Saves clonal baseline sequence for future deep MRD tracking (10⁻⁵ / 10⁻⁶ sensitivity).
CD138 Immunohistochemistry & True Plasma Cell Count
- Immune Staining (CD138 IHC): Evaluates true tissue architecture and cellularity without blood dilution artifacts.
- Diagnostic Cutoffs: <10% (MGUS), 10%–59% (SMM / Active MM with CRAB), or ≥60% (Myeloma Defining Event).
- The Higher Count Rule: If liquid aspirate shows 8% but solid core biopsy shows 25%, international criteria use 25%.
Why You Need a Repeat Biopsy & FISH at Relapse
Up to 30%–50% of late relapses develop new TP53 loss even if standard-risk at baseline, requiring immediate therapy escalation.
Acquiring ≥4 copies of 1q21 shifts disease into ultra-high-risk category, warranting early quadruplet or cellular switches.
Verifies whether plasma cells still express surface targets after prior immunotherapies to guide CAR-T or bispecific selection.
Key Takeaways & Next Steps
- Make comfort part of your plan: Ask ahead of time whether your clinic offers light IV sedation or oral relaxation medicine, and remind the clinician to give the local numbing medicine a couple of minutes to soak into the bone surface.
- Look for the higher percentage and the words "CD138-enriched": Those two details on your pathology report guarantee that neither blood dilution nor normal marrow cells skewed your results.
- Treat relapse as a fresh biological checkup: If your myeloma ever comes back, repeating the bone marrow
FISHtest ensures your next treatment is matched to what the myeloma looks like today, not what it looked like years ago.
5 Questions to Ask Your Doctor
- Can I have sedation along with local numbing for my biopsy?: "To make the procedure as comfortable as possible, do you offer light twilight sedation or a pre-procedure anti-anxiety tablet in addition to the local lidocaine numbing?"
- Will we save a baseline sample for future MRD testing?: "When you draw the first
2 to 3 mLof liquid marrow, can we make sure a baseline DNA sample is archived for future Minimal Residual Disease (MRD) tracking?" - What was the higher plasma cell percentage between my aspirate and core biopsy?: "Once both the liquid smear and the solid
CD138-stained core biopsy are back, what is the higher clonal plasma cell percentage we are using?" - Was my FISH genetic test run on CD138-sorted cells?: "Did the lab perform
CD138magnetic bead sorting before running myFISHpanel, and am I considered standard-risk or high-risk under the newest post-2025 IMS/IMWG criteria?" - At relapse, have my myeloma cells picked up any new genetic changes?: "Compared to my original biopsy at diagnosis, did my relapsed bone marrow show any newly acquired changes like
del(17p), a TP53 mutation, or1q21amplification?"
Next Steps & Related Decision Guides
- [Deep Remission & Stopping Therapy]: Wondering how deep remission goes once your marrow looks clear? Read our MRD Testing Guide to explore NGF and NGS sensitivity milestones.
- [Routine Blood & Urine Tracking]: Need a refresher on M-spike curves, light-chain ratios, and 24-hour urine jugs? Review our Understanding Lab Reports Guide.
- [High-Risk Genetics Playbook]: Did your FISH report show
del(17p),t(4;14), or1q21amplification? Discover adapted frontline and maintenance strategies in our High-Risk Myeloma Guide. - [Advanced Imaging Scans]: Find out how whole-body low-dose CT, MRI, and PET/CT detect lesions that bone marrow samples miss in our Whole-Body Imaging Guide.
- [Relapsed/Refractory Treatment Strategies]: If clonal evolution or disease progression is confirmed, explore modern class-switching options in our Relapsed/Refractory Myeloma Treatment Guide.
References
- National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma, Version 2.2027 (2026). Available at: https://www.nccn.org
- Avet-Loiseau H, Davies FE, Samur MK, et al. International Myeloma Society / International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025.
- Dimopoulos MA, Terpos E, Boccadoro M, et al. EHA-EMN Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma. HemaSphere / Nat Rev Clin Oncol. 2025.
- International Myeloma Foundation (IMF). Patient Handbook for Multiple Myeloma. 2025 Edition. Available at: https://www.myeloma.org
This clinical decision guide is synthesized from international consensus guidelines and peer-reviewed literature for educational purposes only. It does not substitute for professional medical care. Consult your treating hematology-oncology team regarding diagnostic and treatment decisions.
CMDN Care · Myeloma Companion
Organize your lab reports, follow biomarker trends, and prepare questions for your care team with CMDN’s English-language companion for myeloma patients and caregivers.
Open CMDN CareHow CMDN Care worksSign in with Google or a secure email code.
Lab report OCR
Review results extracted from your reports.
Biomarker trends
Keep follow-up results in one place.
Visit preparation
Bring your questions to your care team.
FAQs
- Does a bone marrow biopsy go into my spine, and could it paralyze me?
- No—never. A bone marrow biopsy is taken from the back of your pelvic hip bone (the posterior iliac crest), right below your beltline on the side. It goes nowhere near your spinal cord or spinal nerves, so there is zero risk of paralysis.
- Why can't my doctor just use blood tests instead of doing a bone marrow biopsy?
- Blood tests only measure the abnormal proteins that myeloma cells release into your bloodstream. Only a bone marrow biopsy can look inside the bone marrow 'factory' to count the exact percentage of myeloma cells (10% and 60% diagnostic cutoffs), run FISH genetic tests on the cells' DNA, and save a baseline tumor fingerprint for future Minimal Residual Disease (MRD) testing.
- Why do they take both liquid marrow (aspirate) and a solid piece of bone (core biopsy)?
- The two samples do different jobs. The liquid aspirate lets the lab run genetic FISH testing, flow cytometry, and future MRD tracking. The solid core biopsy (a tiny cylinder of spongy bone the size of a pencil lead) shows how densely the myeloma cells are packed together and gives the most accurate plasma cell percentage.
- Why does my aspirate report say 7% plasma cells while my biopsy report says 30%?
- Myeloma cells grow in patchy clusters inside the marrow, and drawing liquid marrow into a syringe almost always pulls in normal blood that waters down the count (hemodilution). Because the solid CD138-stained core biopsy is not diluted by blood, international guidelines instruct your doctor to always use whichever percentage is higher (30% in this example).
- How do I know if my bone marrow sample was good enough for accurate genetic testing?
- Check for two things: first, the doctor should send the very first 2 to 3 mL of liquid marrow ('first pull') for genetic testing before blood dilution sets in; second, your FISH report should state that it was performed on 'CD138-enriched' (or sorted) plasma cells so normal blood cells do not hide genetic changes.
- I already had a bone marrow biopsy when I was diagnosed. Why do I need another one if my myeloma comes back?
- Myeloma cells can evolve over time. Even if you had standard-risk genetics at diagnosis, surviving myeloma cells can pick up new high-risk genetic changes at relapse—most commonly a newly acquired del(17p) / TP53 mutation or extra copies of chromosome 1 (1q21 amplification). Catching these new changes helps your doctor switch you to stronger therapies like CAR-T cells or bispecific antibodies right away.
Related reading
References used for this guide
- NCCN Clinical Practice Guidelines in Oncology: Multiple Myeloma (Version 2.2027)
- IMS/IMWG Consensus Recommendations on the Definition of High-Risk Multiple Myeloma (J Clin Oncol)
- EHA-EMN Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up of Multiple Myeloma
- International Myeloma Foundation (IMF) Patient Handbook
for their academic support:
for myeloma patients globally